Establishment of a clear cell renal cell carcinoma organoid cohort integrated into the UroCCR clinical database: A feasibility study
Abstract
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is the sixth most common cancer in France. While early-stage survival rates are high in early stages, they decrease significantly in metastatic stages, due to tumor heterogeneity and treatment resistance. The development of reliable preclinical models is essential to improve targeted therapies. This study aimed to evaluate the feasibility of establishing patient-derived ccRCC organoids linked to the UroCCR clinical database. METHODOLOGY: Tumor samples from total or partial nephrectomies performed at Caen University Hospital between November 2023 and March 2024 were processed for organoid culture. Seven culture conditions were tested, including different extracellular matrices (Matrigel, collagen I) and growth factor-enriched media. RESULTS: Organoids were established in 12 of 18 cases (66.7%). Among these, five cultures were successfully expanded and characterized histologically (42%). Organoids were maintained in culture for a median of 52 days and underwent a mean of two passages. Histological analyses showed that organoids retained several morphological features consistent with the original tumors, although variability in CA-IX and CK7 expression was observed. SIGNIFICANCE: This feasibility study demonstrates that ccRCC organoid generation from surgical specimens is achievable but remains limited by variable establishment rates and culture duration. Further optimization and integration of microenvironmental components will be necessary to enhance the translational relevance of this model.
Related
- Fallopian Tube Organoid-Integrated Microfluidic Platform for Real-Time Imaging and Outflow Analysis
- The role of SARS1 in the progression of colorectal cancer: insights from clinical data and organoid models
- Feasibility and immediate effects of a multimodal, dance-integrated educational video package on eye health knowledge and intentions in Nigeria: A pre-post pilot study
- An integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn – ALICE (PRODIGE89 – UCGI44 – ALICE)
- Integrated Multiomic Analysis Reveals an EBV‐Associated MIF–SPP1+ Macrophage Axis Linking Tumor Stemness and Immune Dysfunction in Nasopharyngeal Carcinoma
BibTeX
@article{lefranc2026establishment,
title = {{Establishment of a clear cell renal cell carcinoma organoid cohort integrated into the UroCCR clinical database: A feasibility study}},
author = {R. Lefranc and T. Waeckel and M. Riffet and R. Florent and G. Desmartin and L. Lecouflet and J. Divoux and L. Poulain and X. Tillou and L.B. Weiswald and G. Levallet and C. Bazille},
journal = {Translational Oncology},
year = {2026},
month = sep,
doi = {10.1016/j.tranon.2026.102885},
url = {https://normandie-univ.hal.science/hal-05744529v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Establishment of a clear cell renal cell carcinoma organoid cohort integrated into the UroCCR clinical database: A feasibility study
AU - R. Lefranc
AU - T. Waeckel
AU - M. Riffet
AU - R. Florent
AU - G. Desmartin
AU - L. Lecouflet
AU - J. Divoux
AU - L. Poulain
AU - X. Tillou
AU - L.B. Weiswald
AU - G. Levallet
AU - C. Bazille
PY - 2026
DA - 2026/09/09
JO - Translational Oncology
DO - 10.1016/j.tranon.2026.102885
UR - https://normandie-univ.hal.science/hal-05744529v1
AB - BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is the sixth most common cancer in France. While early-stage survival rates are high in early stages, they decrease significantly in metastatic stages, due to tumor heterogeneity and treatment resistance. The development of reliable preclinical models is essential to improve targeted therapies. This study aimed to evaluate the feasibility of establishing patient-derived ccRCC organoids linked to the UroCCR clinical database. METHODOLOGY: Tumor samples from total or partial nephrectomies performed at Caen University Hospital between November 2023 and March 2024 were processed for organoid culture. Seven culture conditions were tested, including different extracellular matrices (Matrigel, collagen I) and growth factor-enriched media. RESULTS: Organoids were established in 12 of 18 cases (66.7%). Among these, five cultures were successfully expanded and characterized histologically (42%). Organoids were maintained in culture for a median of 52 days and underwent a mean of two passages. Histological analyses showed that organoids retained several morphological features consistent with the original tumors, although variability in CA-IX and CK7 expression was observed. SIGNIFICANCE: This feasibility study demonstrates that ccRCC organoid generation from surgical specimens is achievable but remains limited by variable establishment rates and culture duration. Further optimization and integration of microenvironmental components will be necessary to enhance the translational relevance of this model.
SN - 1944-7124
SN - 1936-5233
ER -